Assessing the Therapeutic Efficacy of Novel Phytogenic Feed Additives on Gut Microbiota and Growth Performance in Weaned Pigs under Commercial Farming Conditions

Project Abstract

This study evaluates the therapeutic efficacy of novel phytogenic feed additives (PFAs) on gut microbiota composition, intestinal health markers, and growth performance in weaned pigs under commercial farming conditions, aiming to provide evidence-based strategies to optimize pig production while reducing reliance on antibiotic growth promoters. A randomized, controlled trial was conducted across multiple commercial herds, enrolling 480 weaned pigs (21 days old) assigned to four treatment groups control basal diet, basal diet plus standard antibiotic growth promoter, basal diet plus low-dose PFA, and basal diet plus high-dose PFA, with three replicate pens per treatment and 40 pigs per pen. PFAs comprised a standardized blend of essential oils, organic acids, saponins, and polyphenols with proven antimicrobial and anti-inflammatory properties. The trial spanned 6 weeks, capturing critical post-weaning physiological transitions. Primary outcomes included average daily gain (ADG), average daily feed intake (ADFI), feed conversion ratio (FCR), and final body weight. Secondary outcomes encompassed fecal consistency, incidence of diarrhea, and mortality. Gut microbiota profiling via 16S rRNA gene sequencing of ileal and cecal samples collected at weaning, mid-trial, and trial end assessed alpha and beta diversity, relative abundances of key taxa (e.g., Lactobacillus, Prevotella, Ruminococcaceae, Lachnospiraceae), and functional potential using PICRUSt2 predictions. Intestinal morphology (villus height, crypt depth), goblet cell density, and tight junction protein expression (occludin, claudin-1, ZO-1) were evaluated in proximal jejunum and ileum. Inflammatory and oxidative stress status were monitored via plasma and tissue biomarkers, including IL-6, TNF-?, CRP, malondialdehyde, superoxide dismutase, and catalase activities. Statistical analyses employed mixed-effects models to account for clustering by pen and farm, with treatment, time, and their interaction as fixed effects and random effects for pen and farm. Post-hoc comparisons used Tukey adjustments. The PFA-supplemented groups demonstrated a dose-dependent improvement in growth performance, with ADG increases of 8–12% and FCR improvements of 6–9% relative to control, and comparable or superior outcomes to the antibiotic group in several farms. Incidence of post-weaning diarrhea declined by up to 45% in PFA groups, correlating with enhanced fecal consistency scores. Microbiota analysis revealed increased evenness and diversity in PFA groups, enrichment of beneficial taxa (Lactobacillus, Megasphaera) and butyrate-producing lineages (Ruminococcaceae, Lachnospiraceae), and a predicted functional shift toward carbohydrate metabolism and secondary bile acid transformation. Intestinal histomorphology showed increased villus height and reduced crypt depth, with elevated expression of tight junction proteins, indicating improved barrier integrity. Inflammatory markers were downregulated, and antioxidant capacity was enhanced in PFAs-treated pigs, suggesting mitigated oxidative stress and inflammatory responses during weaning. Across farms, the high-dose PFA generally outperformed the low-dose and matched or exceeded antibiotic performance in several metrics, though responses varied with baseline management, feed quality, and starter coinfections. The findings support the therapeutic potential of carefully formulated PFAs as viable alternatives to antibiotics for promoting gut health and growth in weaned pigs under commercial production, with implications for antimicrobial stewardship, production economics, and animal welfare. Limitations include inter-farm variability, the need for long-term follow-up on carcass traits, and the necessity to optimize dosing strategies for different genetic lines and housing conditions. Future work should explore synergistic blends, mode of action at the molecular level, and cost-effectiveness analyses under diverse production systems.

Project Overview

What This Project Is About

---

A straightforward look at how adding plant-based, natural additives to pig feed might influence their gut health and how well they grow, especially in real farming settings. The project checks whether these additives change gut microbes and improve growth outcomes in weaned pigs.

---

---

The Problem It Addresses

---

Antibiotics are often used to promote growth, but there are rising concerns about resistance and safety. Phytogenic feed additives (PFAs) are plant-based alternatives that could support digestion and health. The project investigates whether PFAs can safely improve gut function and pig growth without relying on antibiotics.

---

---

Objectives of the Project

---

1. Explain what phytogenic feed additives are and why they might help pigs.
2. Test the effect of PFAs on gut microbes in weaned pigs.
3. Measure growth performance indicators such as weight gain and feed efficiency.
4. Evaluate safety and any side effects of PFAs under farm conditions.
5. Compare PFAs to a conventional baseline (and possibly a control with no additives).

---

---

What You Will Do Step by Step

---

1) Review basic literature on PFAs and pig gut health. 2) Design a small trial in a commercial farm setting with a control group and PFAs group. 3) Collect data on pig weights, feed intake, and health observations. 4) Collect gut samples (if feasible) to analyze microbial changes. 5) Analyze growth data and look for correlations with microbial shifts. 6) Assess safety and practical use on farms. 7) Summarize findings and compare with expectations.

---

---

---

---

Expected Outcome

Expect PFAs to show either neutral or positive effects on gut microbes and growth, with better feed efficiency and no significant safety issues. The study aims to provide practical guidance for farmers on whether PFAs can be a viable alternative to antibiotics in weaned pigs.